CHICAGO (Reuters) - Boston Scientific Corp. on Thursday said the U.S. Food and Drug Administration has approved its second-generation product to treat women with urinary incontinence. The injectable product, called Durasphere EXP, is designed to treat the problem specifically due to sphincter deficiency, the company said. Since the introduction of the first generation Durasphere in 1999, 35,000 patients have been treated, Boston Scientific said.

Copyright © 2003 Reuters Limited. All rights reserved. Republication or redistribution of Reuters Limited content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters Limited. Reuters Limited shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.